The FDA approved Moderna's new mRNA RSV vaccine, bypassing its independent vaccine advisory committee, which typically offers recommendations for such drugs.

The mRNA respiratory syncytial virus (RSV) vaccine from Moderna was licensed by the U.S. Food and Drug Administration (FDA) last week for people 60 years of age and above.

As stated in its approval letter, the FDA approved the drug without consulting its independent vaccine advisory committee, which normally offers recommendati...